NIH National Cancer Institute (NCI)
Outstanding Investigator Award (OIA) (R35 Clinical Trial Not Allowed)

This program requires an Internal Vetting Process.

Internal submission deadline: Thursday, September 5, 2019

See Internal Submission Guidelines for more details.


Dr. Steve Artandi, the Director of the Stanford Cancer Institute, has established the following vetting process for all Stanford Cancer Institute (SCI) faculty interested in applying for this NCI OIA Award.

Although the number of applications per institution is not limited, applications must be vetted locally and a two page letter of recommendation is required. Institutional support for the faculty member's efforts is also mandated.

Dr. Artandi will set up an internal review committee to review potential applications, which will be judged on the basis of a NIH biosketch with current funding and a 1-2 page outline of background and specific aims for a proposal.


Stanford Cancer Institute internal vetting process deadline: September 5, 2019 
Notification of selection and to proceed with a letter of intent: September 18, 2019
For PIs given the approval to proceed with their applications:
NIH letter of intent deadline: 30 days prior to the application deadline: October 7, 2019
Institutional representative (RPM/RMG or CGO/OSR) deadline: October 30, 2019
Application receipt deadline: November 6, 2019

 Program Guidelines

 Amount of Funding

 This R35 award will provide up to $600,000 direct costs (plus indirects) per year for up to 7 years.


  • In response to concerns about sustainable funding for productive investigators, the NCI has reissued an award for institutions to nominate applicants who meet the following eligibility criteria:
  • Applications must be submitted by Institutions who have nominated a Program Director/Principal Investigator (PD/PI) with outstanding cancer research productivity during the last 5 consecutive calendar years.
  • The Institution-nominated PD/PI must have been a PD/PI or Project Leader of a research project, excluding cores, (of a NIH-defined multi-project grant e.g., P01, P50, U54) on an eligible NCI research grant(s) continuously since September 2014. Continuous funding is defined as receiving a Notice of Award as PD/PI for an eligible NCI funded research grant in each Federal Fiscal Year beginning in FY 2014 onward. Continuous funding does not include grants in a funded or unfunded extension. Eligible NCI research grant mechanisms are defined as R01, R15, R33, R37, P01, P50, U01, U54, UM1, U19, U10, DP1, and DP2.
  • Due to the nature of this award, applicants are required to devote at least 6 person months effort to the OIA. Applicants with administrative responsibilities or other duties inconsistent with this time commitment may apply but must reduce those other commitments to accept the award.
  • PDs/PIs with effort on other grant support will be expected to provide, as part of the Just-in-Time information, a detailed explanation describing how effort on his/her other grants will be adjusted, if necessary, to permit 6 person months on the OIA.
  • PD/PIs will need to renegotiate their time and effort on other grant support, if necessary, in order to accommodate the OIA level of effort.
  • In addition, grantee Institutions are expected to:
  • Provide clear and continuing substantial commitment to the PD/PI, for example providing at least 20% salary support for the duration of the award;
  • Agree to relinquish the PD/PI's existing NCI funded single PD/PI and single project research grants to allow them to be consolidated into the OIA

 Purpose and Award Details

The purpose of the National Cancer Institute (NCI) Outstanding Investigator Award is to provide long-term support and increased flexibility for investigators with outstanding records of research productivity to continue or to embark upon a research program of unusual potential in cancer. Candidates for the OIA must be nominated by their applicant organization.

 Internal Submission Guidelines

By September 5, 2019, please submit one PDF file (File name: Last name_NCI_OIA.pdf ) containing the following in the order listed below to:

Gayle White
Project Manager
Stanford Cancer Institute

1) Title page
NCI Outstanding Investigator Award PAR-19-349
PI name, title, department, email address
2) 1-2 page outline of background and specific aims for a proposal
3) NIH Biosketch with current and recent funding


Institutional representative: not applicable. You do not need to send your internal proposal to your RPM/RMG or your CGO/OSR for institutional review and approval. You may submit it directly to Gayle White.  For inquiries regarding the internal selection process, please contact:

Gayle White
Project Manager
Stanford Cancer Institute